Abstract:Background: Skeletal dysplasia is a frequent cause of congenital disproportionate short stature, and genetic defects of cartilage extracellular matrix (ECM) affect growth plate structure and functions. However, precise diagnosis remains difficult due to high heterogeneity of phenotypes. Objective: We sought to identify phenotype spectrum and genetic causes for Chinese patients with skeletal related short stature. Patients and Methods: 86 short stature patients clinically diagnosed or suspected of skeletal dysplasia from 2013 to 2018 were included, and clinical information were systematically collected. Next generation sequencing (NGS) was informed and conducted in all these patients, and pathogenicity of candidate genes were analyzed based on clinical data. Results: 45 of the 86 patients had confirmed mutations, and 46.7% of them (21 to 45) were identified with heterozygous mutations relevant of cartilage extracellular matrix. 19 variants of 5 genes were identified including 9 of COL2A1, 1 of COL9A1, 4 of COL10A1, 4 of COMP and 3 of FBN1. The age at diagnosis was 9.47±5.46 years, and the height SDS was -4.78±1.65. The phenotypic spectrum ranged from proportionate short stature with mild upper limb deformity to typical, severe disproportionate manifestations. Deformities of limbs and vertebral anomalies were more frequently encountered presentations. Patients with COL2A1 mutations were more likely to show facial features, pectus carinatum, scoliosis and epiphyseal dysplasia while those with COL10A1 variants mainly presented genu varum and scoliosis. 5 probands (2 COL10A1, 3 COL2A1) were maternal inherited and 12 of 14 affected family members were female. Individuals with COMP variants had the severest height loss (medium height, -6.24 SDS; range, -7.56 to -5.97) and showed typical short-limb dwarfism, irregular epiphyses and dysfunction of joints in early ages. None of the patients with FBN1 mutations had significant facial features or spinal deformity, but bowing of limbs, brachydactyly and decreased joint mobility were visible. 4 of 20 individuals underwent rhGH therapy but had limited effects. Facial dysmorphism was a significant feature to exclude patients with FGFR3 mutations, while limb and spine deformities were frequently encountered in both ECM and FGFR3 patients. Conclusion: NGS is an efficient tool to identify genetic cause of skeletal dysplasia due to its clinical and molecular heterogeneity, and variants of genes encoding cartilage extracellular matrix are the most common cause. Sources of Research Support: The National Key Research and Development Program of China” (No. 2016YFC0901501) and CAMS Innovation Fund for Medical Science (CAMS-2016-I2M-1-002). Unless otherwise noted, all abstracts presented at ENDO are embargoed until the date and time of presentation. For oral presentations, the abstracts are embargoed until the session begins. Abstracts presented at a news conference are embargoed until the date and time of the news conference. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.

Growth-Promoting Therapies May Be Useful in Short Stature Patients with Nonspecific Skeletal Abnormalities Caused by Acan Heterozygous Mutations: Six Chinese Cases and Literature Review

A High Proportion of Novel <i>ACAN</i> Mutations and Their Prevalence in a Large Cohort of Chinese Short Stature Children

Genotype and phenotype in patients with ACAN gene variants: Three cases and literature review

Case analysis and literature review of 3 children with short stature with ACAN gene mutation

Familial Short Stature Caused by ACAN Gene Mutation:A Familial Case Report

ACAN Gene Mutations in Short Children Born SGA and Response to Growth Hormone Treatment

Progress on growth promoting therapies other than growth hormone.

Novel Pathogenic ACAN Variants in Non-Syndromic Short Stature Patients.

Growth Curves of Chinese Children with Androgen Insensitivity Syndrome: A Multicenter Registry Study

Clinical Characteristics of Short-Stature Patients With an NPR2 Mutation and the Therapeutic Response to rhGH.

Long-Term Efficacy and Safety of Recombinant Human Growth Hormone in Children Born Small for Gestational Age.

Novel aggrecan variant, p. Gln2364Pro, causes severe familial nonsyndromic adult short stature and poor growth hormone response in Chinese children.

Clinical Characteristics of Pathogenic ACAN Variants and 3-Year Response to Growth Hormone Treatment: Real-World Data

Genetic studies of 77 cases of short stature with unknown etiology

Growth Concerns in Coffin–Lowry Syndrome: A Case Report and Literature Review

Long-Term Outcomes of Treatments for Central Precocious Puberty or Early and Fast Puberty in Chinese Girls

SUN-LB008 Clinical Phenotype and Genotype Analysis of Short Stature Patients with Skeletal Dysplasia

Identification of short stature caused by SHOX defects and therapeutic effect of recombinant human growth hormone

High frequency of pathogenic ACAN variants including an intragenic deletion in selected individuals with short stature

Efficacy of Recombinant Human Growth Hormone Treatment in Children Born Small for Gestational Age with Syndromic and Non-Syndromic Short Stature

Short Stature in Klinefelter Syndrome From Aggrecan Mutation